Last reviewed · How we verify
Methotrexate plus ERB-041 for 12 weeks
Methotrexate plus ERB-041 for 12 weeks is a Small molecule drug developed by Wyeth is now a wholly owned subsidiary of Pfizer. It is currently in Phase 2 development.
At a glance
| Generic name | Methotrexate plus ERB-041 for 12 weeks |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methotrexate plus ERB-041 for 12 weeks CI brief — competitive landscape report
- Methotrexate plus ERB-041 for 12 weeks updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI
Frequently asked questions about Methotrexate plus ERB-041 for 12 weeks
What is Methotrexate plus ERB-041 for 12 weeks?
Methotrexate plus ERB-041 for 12 weeks is a Small molecule drug developed by Wyeth is now a wholly owned subsidiary of Pfizer.
Who makes Methotrexate plus ERB-041 for 12 weeks?
Methotrexate plus ERB-041 for 12 weeks is developed by Wyeth is now a wholly owned subsidiary of Pfizer (see full Wyeth is now a wholly owned subsidiary of Pfizer pipeline at /company/wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer).
What development phase is Methotrexate plus ERB-041 for 12 weeks in?
Methotrexate plus ERB-041 for 12 weeks is in Phase 2.